Gansert, Jennifer Lorraine,Anderson, Abraham Antonio,Gorski, Kevin
申请号:
AU2018260777
公开号:
AU2018260777A1
申请日:
2018.04.27
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.